Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial
Clinical trial NCT04687163 · UNKNOWN
Trial details
- NCT number
- NCT04687163
- Sponsor
- Sun Yat-sen University
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-30
- Primary completion
- 2022-12-01
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.